Last reviewed · How we verify
NCT04327479
Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection
trial testing Assessment of cardiovascular diseases and cardiovascular risk factors in Cardiovascular Diseases in 728 participants. Completed in 25 July 2022.
25 March 2022
Quick facts
| Lead sponsor | University Hospital, Essen |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 728 |
| Start date | 26 March 2020 |
| Primary completion | 25 March 2022 |
| Estimated completion | 25 July 2022 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Assessment of cardiovascular diseases and cardiovascular risk factors
Conditions studied
- Cardiovascular Diseases — all drugs for Cardiovascular Diseases →
- Cardiovascular Risk Factor — all drugs for Cardiovascular Risk Factor →
- SARS — all drugs for SARS →
Sponsor
University Hospital, Essen
Who can join
18 and older, any sex, with Cardiovascular Diseases or Cardiovascular Risk Factor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infects host-cells via ACE2-receptors, which leads to pneumonia (COVID-19) but also can lead to myocarditis (acute myocardial injury) and chronic damage to the cardiovascular system. Therefore, cardiovascular protection may be necessary when treating patients with COVID-19 infection. This may especially be necessary in patients with cardiovascular diseases, risk factors, and co-medication.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Ventricular assist device for a coronavirus disease 2019-affected heart.
Rassaf T, Totzeck M, Mahabadi AA, Hendgen-Cotta U, et al · · 2021 · cited 11× · PMID 33219613 · DOI 10.1002/ehf2.13120 -
Response to recent commentaries regarding the involvement of angiotensin-converting enzyme 2 (ACE2) and renin-angiotensin system blockers in SARS-CoV-2 infections.
Speth RC. · · 2020 · cited 11× · PMID 32304146 · DOI 10.1002/ddr.21672 -
Frequency and prognosis of CVD and myocardial injury in patients presenting with suspected COVID-19 - The CoV-COR registry.
Mahabadi AA, Mincu R, Dykun I, Michel L, et al · · 2023 · cited 3× · PMID 36776683 · DOI 10.1016/j.ijcha.2023.101184
Verify or expand the search:
- PubMed search for NCT04327479
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cardiovascular Diseases
Currently open trials in the same condition.
- NCT07442578 — Impact of Exercise Intensity on Cardiac Health in Young Adult Survivors of Childhood Cancer: The PULSE Trial · NA · active not recruiting
- NCT07426263 — Effectiveness of a Therapeutic Education Program on Female Sexuality in Women Attending Cardiac Rehabilitation. · NA · active not recruiting
- NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
- NCT07324278 — Hybrid Stroke Rehab With Mirror Priming · NA · recruiting
- NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting
Other University Hospital, Essen trials
Trials by the same sponsor.
- NCT07409584 — Mental Health and Suicidality in Glioblastoma Patients in Germany · recruiting
- NCT07359690 — Multimodal Analysis of Endomyocardial Biopsies · recruiting
- NCT06388369 — Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer · Phase 1, PHASE2 · terminated
- NCT07130526 — Distrupt Stiffness Trial · NA · recruiting
- NCT07343466 — Quality of Life and the Influence of Stress on the Postoperative Course of Patients After Device Implantation · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04327479 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Essen
- Last refreshed: 3 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04327479.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing